Article Text

PDF
Functional variants of the macrophage migration inhibitory factor do not infer risk of cardiovascular disease in rheumatoid arthritis
  1. T R D J Radstake1,
  2. J Fransen1,
  3. P L C M van Riel1,
  4. E Toonen2,
  5. M Coenen2,
  6. R Donn3
  1. 1
    Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
  2. 2
    Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
  3. 3
    ARC/EU and The Centre for Molecular Medicine, University of Manchester, UK
  1. Dr T R D J Radstake, Department of Rheumatology and Experimental Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Center, The Netherlands, Geert Grooteplein 8, P.O. Box 9101, 6500 HB Nijmegen; T.Radstake{at}reuma.umcn.nl

Statistics from Altmetric.com

In the last decade it became apparent that patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD) leading to an excess mortality of approximately 25%.13 Nowadays a substantial body of evidence indicates that atherosclerosis shares many features with inflammatory disease, such as RA, and that the involved inflammatory mediators are likely to be similar. More recently, evidence has emerged for the involvement of macrophage migration inhibitory factor (MIF) both in RA and atherosclerosis suggesting that MIF might form the link between RA and the increased incidence of CVD in this condition. Two known single nucleotide polymorphisms in the MIF gene have been …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.